scholarly journals Detection of HPV and Human Chromosome Sites by Dual-Color Fluorescence In Situ Hybridization Reveals Recurrent HPV Integration Sites and Heterogeneity in Cervical Cancer

2021 ◽  
Vol 11 ◽  
Author(s):  
Jinfeng Xiong ◽  
Jing Cheng ◽  
Hui Shen ◽  
Ci Ren ◽  
Liming Wang ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
High Frequency ◽  
Integration Site ◽  
Cancer Tissue ◽  
Site Specific ◽  
Sequencing Technologies ◽  
Cervical Cancer Tissue ◽  
Dual Color ◽  
Integration Sites

Human papillomavirus (HPV) integration in the human genome is suggested to be an important cause of cervical cancer. With the development of sequencing technologies, an increasing number of integration “hotspots” have been identified. However, this HPV integration information was derived from analysis of whole cervical cancer tissue, and we know very little about the integration in different cancer cell subgroups or individual cancer cells. This study optimized the preparation of probes and provided a dual-color fluorescence in situ hybridization (FISH) method to detect HPV integration sites in paraffin-embedded cervical cancer samples. We used both HPV probes and site-specific probes: 3p14 (FHIT), 8q24 (MYC), 13q22 (KLF5/KLF12), 3q28 (TP63), and 5p15 (TERT). We detected HPV signals in 75 of the 96 cases of cervical cancer; 62 cases showed punctate signals, and 13 cases showed diffuse punctate signals. We identified 3p14 as a high-frequency HPV integration site in 4 cervical cancer cases. HPV integration at 8p14 occurred in 2 cases of cervical cancer. In the same cervical cancer tissue of sample No.1321, two distinct subgroups of cells were observed based on the HPV probe but showed no difference in cell and nucleus morphology. Our study provides a new method to investigate the frequent HPV integration sites in cervical cancer and reports the heterogeneity within cervical cancer from the perspective of HPV integration.

Toll-like receptor 7 and 9 (TLR 7 and TLR 9) expression in biopsies of in situ cervical cancer.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e15584-e15584
Author(s):  
Mario Adan Moreno-Eutimio ◽  
Raul Aragon-Franco ◽  
Constantino Lopez-Macias ◽  
Alejandro J. Silva ◽  
Horacio Astudillo
Keyword(s):  
Cervical Cancer ◽  
Cancer Tissue ◽  
Histopathological Diagnosis ◽  
National Defense ◽  
Cervical Cancer Tissue ◽  
Significant Difference ◽  
Health Directorate ◽  
Positive Results ◽  
Inflammatory Tissue

e15584 Background: In order to analyze the expression of TLR 7 and TLR 9 in cervix biopsies, we evaluated the expression of these TLRs in cervical carcinoma in situ tissue and peritumoral inflammatory tissue biopsies by immunohistochemistry. Methods: We reviewed 276 uterine cervix biopsies of Clinical Specialties Women's Health Directorate of the Ministry of National Defense (between 2009-2010); the biopsies have the following histopathological diagnosis: 124 CIN I, 68 CIN II, 34 CIN III, 21 invasive cancer and 29 cancer in situ. Results: It was observed that peritumoral inflammatory tissue receptor was expressed positively in 89.6% in cervical cancer tissue in situ, the receptor was expressed positively in 68.9% and the negative expression was 31.1%, proving that in the peritumoral inflammatory tissue compared with in situ cervical cancer was increased expression of TLR 7. In the case of the expression of TLR 9, peritumoral inflammatory tissue, expressed positively in 24 samples and 5 samples were negative expression in the tissue in situ cervical cancer samples identified 20 positive and 9 negative samples. By analyzing the intensity of the expression of TLR 7 in cervical cancer tissue in situ, we found 16 samples with focal positive (+), 3 samples with diffuse positive (+ +) and 1 sample with positive (+ + + ), while in peritumoral inflammatory tissue found 13 samples with focal positive (+), 10 samples with diffuse positive (+ +) and 3 samples with positive results (+++). By analyzing the intensity of the expression of TLR 9 in cervical cancer tissue in situ, we found 14 samples with focal positive (+), 5 samples with diffuse positive (+ +) and 1 sample with positive (+), in contrast to the peritumoral inflammatory tissue was found 7 samples with focal positive (+), 13 samples tested positive diffuse (+ +) and 4 samples with positive results (+++). Conclusions: These results show that no significant difference between the expression of TLR 7 () and TLR 9 () in the peritumoral inflammatory tissue and tissue in situ cervical cancer found a decrease in the expression of TLR 7 and TLR 9 in tissue in situ cervical cancer compared with the expression in the peritumoral tissue inflammation.

scholarly journals IL-10, IL-15, IL-17, and GMCSF levels in cervical cancer tissue of Tanzanian women infected with HPV16/18 vs. non-HPV16/18 genotypes

2015 ◽  
Vol 10 (1) ◽  
Author(s):  
Adriana C Vidal ◽  
David Skaar ◽  
Rachel Maguire ◽  
Seyram Dodor ◽  
Laura W Musselwhite ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Cancer Tissue ◽  
Cervical Cancer Tissue

scholarly journals The E545 Mutation of PIK3CA in Cervical Cancer Promotes the Survival by Several Different Pathways

2021 ◽  
Author(s):  
Yan Chen ◽  
Ma-Chi Yuan ◽  
Jia-Zhen Shi ◽  
Xia Zhao ◽  
Nan He ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Differential Expression ◽  
Bioinformatics Analysis ◽  
Cancer Tissue ◽  
Ppi Network ◽  
Tissue Samples ◽  
Cervical Cancer Tissue ◽  
Differential Expression Genes ◽  
High Degree

Abstract Backgroud: The E545 mutation of PIK3CA in Cervical cancer is frequently happened. But the role of E545 mutation of PIK3CA in Cervical cancer is not clear.Methods: In this study, we analysised the molecular signatures of E545 mutation Cervical cancer by bioinformatics methods.Results: We collected transcriptome sequencing results of 227 no mutation cervical cancer tissue samples and 36 mutation cervical cancer tissue samples, then analyzed the data combining bioinformatics methods. A total of 5 differential expression miRNAs were obtained, including 3 up-regulated miRNAs, 1 down-rugulated miRNA. A total of 174 differential expression genes were obtained, including 132 up-regulated genes, 40 down-rugulated genes. GO analysis suggested that the up-regulated DEGs were mainly enriched in transcription factor activity, leukotriene signaling pathway and so on. Besides, we constructed a PPI network with DEGs to screen the top hub genes with a relatively high degree of connectivity. Among them CAV1, KRT20, FOS, had a degree of connectivity larger than 5 and functioned as hub module genes to promote the survival of E545 mutation cervical cancer. We also identified different miRNA-DEG axis, including hsa-mir-449a-AXL, hsa-mir-508-CGA, COL15A1, NNMT, hsa-mir-552-CHST6, NWD1. These axis regulated the survival of E545 mutation cervical cancer togetherly. Conclusions: In conclusion, this study identified DEGs and screened the key genes and pathways closely related to E545 mutation in Cervical cancer by bioinformatics analysis, These results might hold promise for finding potential therapeutic targets of cervical cancer harboring E545 mutation of PI3KCA.

scholarly journals Diagnostic Availability of Estrogen Receptor Alpha mRNA on Cervical Cancer Tissue

2018 ◽  
Vol 50 (4) ◽  
pp. 449-456
Author(s):  
Geehyuk Kim ◽  
Kwangmin Yu ◽  
Jungho Kim ◽  
Seoyong Kim ◽  
Sunyoung Park ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Estrogen Receptor ◽  
Estrogen Receptor Alpha ◽  
Cancer Tissue ◽  
Receptor Alpha ◽  
Cervical Cancer Tissue

scholarly journals A high yield gold nanoparticle-based DNA isolation method for human papillomaviruses genotypes from cervical cancer tissue samples

2019 ◽  
Author(s):  
Noorossadat Seyyedi ◽  
Fatemeh Farjadian ◽  
Ali Farhadi ◽  
Gholamreza Rafiei Dehbidi ◽  
Reza Ranjbaran ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Dna Sequences ◽  
Hpv Infection ◽  
Human Papillomaviruses ◽  
High Yield ◽  
Cancer Tissue ◽  
Purification Method ◽  
Tissue Samples ◽  
Hpv Dna ◽  
Cervical Cancer Tissue

Gold nanoparticles (AuNPs) are commonly used in biosensors of various kinds. The purification of DNA from cancer tissues is an important step in diagnostic and therapeutic development, but current methods are not optimal. Many cervical cancer patients are also susceptible to high-risk human papillomavirus (HR-HPV) infection. Accurate viral diagnosis has so far relied on the extraction of adequate amounts of DNA from formalin-fixed, paraffin-embedded (FFPE) tissue samples. Since the sensitivity and specificity of commercially available purification kits are not optimal, we designed a DNA purification method based on AuNPs to purify sufficient amounts of HR-HPV DNA from cervical cancer tissue samples. AuNPs were coated with a series of oligonucleotide probes to hybridize to specific DNA sequences of HR-HPV genotypes. With this method, we recovered 733 out of 800 copies of type-specific HPV DNA with complete specificity, compared to 36 copies with a standard commercial kit (Qiagen FFPE).

Sign in / Sign up

Export Citation Format

Share Document